丙酸氟替卡松吸入治疗5岁以下哮喘患儿的临床效果及作用机制

Clinical Effect and Mechanism of Inhalation of Fluticasone Propionate in the Treatment of Children with Asthma Under 5 Years of Age

目的探讨丙酸氟替卡松吸入治疗5岁以下哮喘患儿的临床效果及作用机制。方法选取我院2015年1月—2017年1月收治的5岁以下哮喘患儿120例,根据入院时间随机分为对照组及观察组,每组各60例。两组均予常规治疗,在此基础上,对照组予布地奈德混悬液吸入治疗,观察组予丙酸氟替卡松气雾剂吸入治疗。观察两组临床疗效及不良反应发生情况,记录治疗前后血清神经营养因子-3(NT-3)及嗜酸粒细胞(EOS)的水平变化。结果观察组、对照组临床总有效率分别为91.67%、76.67%,差异有统计学意义(P=0.024)。与本组治疗前比较,两组治疗后NT-3及EOS水平均降低,差异有统计学意义(P<0.05);与对照组比较,观察组治疗后NT-3及EOS水平显著降低,差异有统计学意义(P<0.05)。两组治疗过程中均未出现严重不良反应。结论丙酸氟替卡松吸入治疗5岁以下哮喘患儿可能通过降低NT-3及EOS水平,从而控制气道炎症反应,临床疗效显著,安全性高。

Objective To investigate the clinical effect and mechanism of inhalation of Fluticasone Propionate in the treatment of children with asthma under 5 years of age. Methods A total of 120 children with asthma under 5 years of age that were admitted to our hospital from January 2015 to January 2017 were selected. According to the admission time, they were randomly divided into two groups： the control group and the observation group, with 60 children in each group. Children in the two groups were treated with conventional treatment. On this basis, the control group was treated with budesonide suspension for inhalation, and the observation group was treated with inhalation aerosol （Fluticasone Propionate）. The clinical efficacy and adverse reactions of the two groups were observed, and the changes of serum levels of neurotrophin-3 （NT-3） and eosinophils （EOS） before and after treatment were recorded. Results The total effective rates of the observation group and the control group were 91.67% and 76.67% respectively, and the difference was statistically significant （ P =0.024）. Compared with those before treatment, the levels of NT-3 and EOS were decreased after treatment in the two groups, and there were significant differences （ P 〈0.05）. Compared with the control group, the levels of NT-3 and EOS were decreased significantly in the observation group after treatment, and the difference was statistically significant （ P 〈0.05）. No serious adverse reactions were observed in the two groups during the treatment. Conclusion Inhalation of Fluticasone Propionate in the treatment of asthma in children under 5 years of age may control airway inflammation by reducing NT-3 and EOS levels, which has significant clinical efficacy and safety.